Efficacy News and Research

RSS

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, "Live Cancer Vaccines."

29 Jan 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

WOUNDS article profiles efficacy of Quick-Med's antimicrobial BIOGUARD dressings

Quick-Med Technologies, Inc. announced today that the February 2011 issue of WOUNDS, the leading peer-reviewed journal in the wound care field, will feature an article authored by Quick-Med's Albina Mikhaylova, PhD. The article profiles the safety and antimicrobial efficacy of cutting edge antimicrobial dressings employing Quick-Med's patented NIMBUS technology and marketed by Derma Sciences, Inc. under its BIOGUARD® trademark.

28 Jan 2011

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

In a previous study, rheumatoid arthritis (RA) patients who failed to respond to methotrexate were shown to experience positive results with fostamatinib disodium (R788), an oral spleen tyrosine kinase (Syk) inhibitor that is thought to block immune cell signaling involved with bone and cartilage destruction. In the current study, RA patients who failed to respond to biologic agents were studied.

28 Jan 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

CSL Behring receives marketing approval for HAE drug Berinert in Israel

CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.

28 Jan 2011

Discovery of aldose reductase enzyme can result in new therapies for asthma and COPD

Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease.

28 Jan 2011

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

28 Jan 2011

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual and treatment of all subjects in its Phase 1 clinical trial of PV-10 for liver cancer.

27 Jan 2011

FDA grants 510(k) clearance to Sonitus Medical's SoundBite Hearing System

Sonitus Medical, Inc., a medical device company that manufactures the world's first non-surgical and removable hearing prosthetic to transmit sound via the teeth, today announced that it has received FDA clearance for its SoundBite Hearing System. The FDA 510(k) clearance is the first for the company and the product.

27 Jan 2011

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor® (ibuprofen) Injection in treating post-operative pain in hospitalized patients. A Phase III study published in the peer-reviewed journal Pain Practice concluded that IV ibuprofen significantly reduced both morphine use and self-reported pain intensity in patients recovering from abdominal hysterectomy compared to morphine alone.

27 Jan 2011

TD2 and Flagship Biosciences offer combined oncology and pathology services

TGen Drug Development (TD2) and Flagship Biosciences today announced a strategic alliance that should help speed new drugs safely into human testing and quickly benefit cancer patients.

27 Jan 2011

IEHA, Cintas release list of best practices for reducing HAIs within healthcare facility

In lieu of recent changes in guidelines from the Centers for Disease Control calling for increased cleaning performance and integration of new auditing controls to regulate cleaning efficacy, Cintas Corporation and the International Executive Housekeepers Association today released a list of best practices for reducing healthcare acquired infections and enhancing levels of cleanliness within a healthcare facility.

27 Jan 2011

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced it has been granted Food and Drug Administration conditional Investigational Device Exemption approval to evaluate the safety and effectiveness of its CorPath® 200 System in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary interventions procedures.

27 Jan 2011

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

AB Science SA, a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 3 study evaluating masitinib in severe persistent asthma.

27 Jan 2011

Metanx promotes restoration of lost cutaneous sensation in Diabetic Neuropathy patients

PamLab L.L.C., developer and marketer of Metanx®, announced today that the results of a study to determine if nutritional management with Metanx® improves numbness in the feet of patients with Diabetic Neuropathy (DN) was published in the fourth quarter 2010 issue of Reviews in Neurological Diseases. The study demonstrated that Metanx®, a medical food available by prescription, promotes restoration of lost cutaneous sensation in DN patients.

27 Jan 2011

Study: Removal of B lymphocytes can reverse aging process

Researchers at the Technion-Israel Institute of Technology have discovered a way to reverse the aging process by removing old B lymphocytes from old mice, and forcing the production of young, potent cells to replace them.

27 Jan 2011

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Cancer researchers at Princess Margaret Hospital (PMH) have discovered that targeting an enzyme called Uroporphyrinogen Decarboxylase (UROD) can sensitize diseased tissue to radiation and chemotherapy, which could mean fewer side effects for individuals with head and neck cancer.

27 Jan 2011

Efficacy News and Research

Scientists to commence new DNA vaccine trial for use in patients with leukemia

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

WOUNDS article profiles efficacy of Quick-Med's antimicrobial BIOGUARD dressings

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

CSL Behring receives marketing approval for HAE drug Berinert in Israel

Discovery of aldose reductase enzyme can result in new therapies for asthma and COPD

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

Provectus announces completion of PV-10 Phase 1 trial in patients with liver cancer

FDA grants 510(k) clearance to Sonitus Medical's SoundBite Hearing System

Phase III study affirms safety and efficacy of Cumberland's Caldolor for post-operative pain

TD2 and Flagship Biosciences offer combined oncology and pathology services

IEHA, Cintas release list of best practices for reducing HAIs within healthcare facility

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

AB Science initiates recruitment in masitinib phase 3 study in severe persistent asthma

Metanx promotes restoration of lost cutaneous sensation in Diabetic Neuropathy patients

Study: Removal of B lymphocytes can reverse aging process

Targeting UROD enzyme boosts effects of radiotherapy and chemotherapy in head, neck tumors

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News